The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: A comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34(cdc2)

Cancer

Volumn 85, Issue 7, 1999, Pages 1569-1576

  Kallakury, Bhaskar V S ^a,b   Sheehan, Christine E ^a   Rhee, Sue J ^a   Fisher, Hugh A G ^a   Kaufman Jr , Ronald P ^a   Rifkin, Matthew D ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Cyclin A; Cyclin B1; Immunohistochemistry; Ki 67; p120; Prognosis; Proliferating cell nuclear antigen; Prostate

Indexed keywords

CELL NUCLEUS ANTIGEN; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLINE; KI 67 ANTIGEN; NUCLEAR PROTEIN;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; DNA CONTENT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; CDC2 PROTEIN KINASE; CYCLIN A; CYCLIN B; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NUCLEAR PROTEINS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033120419     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990401)85:7<1569::AID-CNCR19>3.0.CO;2-M     Document Type: Article

References (37)

1. Parker SL, Tone T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997;80:753-63.
3. Fonagy A, Swiderski C, Wilson A, Bolton WE, Kenyon N, Freeman JW. Cell cycle regulated expression of nucleolar antigen P120 in normal and transformed human fibroblasts. J Cell Physiol 1993;154:16-27.
4. Fonagy A, Swiderski C, Ostrovsky AM, Bolton WE, Freeman JW. Effect of nucleolar P120 expression level on the proliferation capacity of breast cancer cells. Cancer Res 1994;54: 1859-64.
5. 1 phase. Cancer Res 1988; 48:1244-51.
6. Freeman JW, Hazelwood JE, Bondada V, Ciball ML, Fonagy A, Ochs R, et al. Proliferation-related nucleolar antigen P145 and P120 associated with separate nucleolar elements and differences in tissue distribution. Cancer Commun 1989;1: 367-72.
7. Freeman JW, Bondada V. Inhibition of cell proliferation by microinjection of antibodies to nucleolar antigen P120. Proc Am Assoc Cancer Res 1990;31:261.
8. Ueki T, Nakayama Y, Sugao Y, Kohno K, Matsuo K, Sugimoto Y, et al. Significance of the expression of proliferation-associated nucleolar antigen p120 in human colorectal tumors. Hum Pathol 1997;27:74-9.
9. Uchiyama B, Saijo Y, Kumano N, Abe T, Fujimura S, Ohkuda K, et al. Expression of nucleolar protein p120 in human lung cancer: difference in histological types as a marker for proliferation. Clin Cancer Res 1997;3:1873-7.
10. Freeman JW, McGrath P, Bondada V, Selliah N, Ownby H, Maloney T, et al. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Cancer Res 1991;51:1973-8.
11. McGrath PC, Holley DT, Hamby LS, Mattingly CA, Freeman JW. Prospective study correlating P120 antigen expression with established prognostic factors in breast cancer. Surg Oncol 1994;3:69-77.
12. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
13. Sherr CJ. G1 phase progression: cyclin on cue. Cell 1994;79: 551-5.
14. Shiozawa T, Xin L, Nikaido T, Fujii S. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Int J Gynecot Pathol 1997;16:348-53.
15. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, et al. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 1996;56:4159-63.
16. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31:13-20.
17. Raymond WA, Leong ASY, Bolt JW, Milios J, Jose JS. Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining. J Pathol 1988;156:161-7.
18. Gallee MPW, Visser-de Jong E, Ten Kate FJV, Schroeder FH, Vander-Kwast TH. Monoclonal antibody Ki-67 defined growth faction in benign prostatic hyperplasia and prostatic cancer. J Urol 1989;142:1342-6.
19. Hepburn PJ, Glynne-Jones E, Goddard L, Gee JMW, Harper ME. Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. Histochem J 1995;27: 196-203.
20. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prognostic carcinoma. J Pathol 1992;168:7-13.
21. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
22. Scalzo D, Kallakury BVS, Gaddipati RV, Sheehan CE, Keys HM, Savage D, et al. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas. Am J Clin Pathol 1998;109:163-8.
23. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 1993;72:3020-8.
24. Cox DR. Regression models in life tables. J R Stat Soc 1972; 32:187-98.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957;53:457-81.
26. Perlaky L, Valdez BC, Busch RK, Larson RG, Jhiang SM, Zhang WW, et al. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res 1992; 52:428-36.
27. Fonagy A, Swiderski C, Dunn M, Freeman JW. Antisense mediated specific inhibition of p120 protein expression prevents G1 to S-phase transition. Cancer Res 1992;52:5250-6.
28. Bocker T, Bittinger A, Wieland W, Buettner R, Fauser G, Hofstaedter F, et al. In vitro and ex vivo expression of nucleolar proteins B 23 and p120 in benign and malignant epithelial lesions of the prostate. Mod Pathol 1995;8:226-31.
29. Migaldi M, Barbolini G, Trere D, Criscuolo M, Martinelli AM, Zunarelli E. Immunohistochemical detection of nucleolar protein p120 in paraffin-embedded tissues. Histochem J 1997;29:661-8.
30. Freeman JW, Hazelwood JE, Auerbach P, Busch H. Optimal loading of scrapped HeLa cells with monoclonal antibodies to the proliferation associated Mr 120,000 nucleolar antigen. Cancer Res 1988;48:5246-50.
31. Perlaky L, Saijo Y, Busch RK, Bennett CF, Mirabelli CK, Crooke ST, et al. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anticancer Drug Des 1993;8:3-14.
32. Saijo Y, Perlaky L, Valdez BC, Busch RK, Henning D, Zhang WW, et al. The effect of antisense p120 construct on p120 expression and cell proliferation in human breast cancer MCF-7 cells. Cancer Lett 1993;68:95-104.
33. Wang A, Yoshimi N, Suzui M, Yamaguchi A, Tarao M, Mori H. Different expression patterns of cyclin A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol 1996;122: 122-6.
34. Wang J, Chenivesse X, Henglin B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990;343:555-7.
35. cdc2 expression and normal p53 suppresses cyclin A expression. Exp Cell Res 1994; 210:94-101.
36. Nemoto R, Kawamura H, Miyakawa I, Uchida K, Hattori K, Koiso K, et al. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)/cyclin in human prostate adenocarcinoma. J Urol 1993;149:165-9.
37. Harper ME, Goddard L, Wilson DW, Matanhelia SS, Conn IG, Peeling WB, et al. Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 1992;21:75-84.